Timothy Asmis
Overview
Explore the profile of Timothy Asmis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Groarke J, Crawford J, Collins S, Lubaczewski S, Roeland E, Naito T, et al.
N Engl J Med
. 2024 Sep;
391(24):2291-2303.
PMID: 39282907
Background: Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated...
2.
Al Mansor E, Adamiak A, Asmis T
Case Rep Oncol
. 2024 Jan;
17(1):49-55.
PMID: 38188481
Introduction: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder brought on by pathogenic mutations in the tumor suppressor gene. LFS is characterized by a high lifetime risk of developing...
3.
Cheung W, Samimi S, Ma K, Knight G, Kassam S, Colwell B, et al.
Clin Colorectal Cancer
. 2023 Nov;
23(1):46-57.e4.
PMID: 38007297
Background: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer...
4.
Al-Mansor E, Mahoney M, Chenard-Poirier M, Ramjeesingh R, Nair V, Kennedy E, et al.
Curr Oncol
. 2023 Sep;
30(9):8172-8185.
PMID: 37754508
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023 was held in Quebec City, Quebec 2-4 February 2023. The purpose of the conference was to develop consensus statements on emerging...
5.
Alfagih A, AlJassim A, Alqahtani N, Vickers M, Goodwin R, Asmis T
Curr Oncol
. 2023 Aug;
30(8):7508-7519.
PMID: 37623025
(1) Aim: The prevalence and incidence of small bowel NETs have increased significantly over the past two decades. This study aims to report the 10-year experience of SB-NET management at...
6.
Siddiqui Z, Marginean H, Leung M, Asmis T, Vickers M, Goodwin R
J Gastrointest Oncol
. 2023 Jul;
14(3):1488-1495.
PMID: 37435213
Background: Treatment for metastatic neuroendocrine tumors (NETs) is often with somatostatin analogues (SSA) such as lanreotide in the first-line setting. Real world use of lanreotide in Canada is not well...
7.
Alfagih A, Alrehaili M, Asmis T
Curr Oncol
. 2022 Oct;
29(10):7439-7449.
PMID: 36290862
(1) Small bowel adenocarcinoma (SBA) is one of the predominant primary small bowel cancers that has a dismal outcome. We aim to report 10 years of experience in SBA management...
8.
Alfagih A, AlJassim A, Alshamsan B, Alqahtani N, Asmis T
Curr Oncol
. 2022 Oct;
29(10):7148-7157.
PMID: 36290839
(1) Background: The management of gastrointestinal stromal tumors (GIST) has significantly evolved over the last two decades, with the introduction of tyrosine kinase inhibitors (TKI). We aim to report 10...
9.
Auer R, Ott M, Karanicolas P, Brackstone M, Ashamalla S, Weaver J, et al.
BMJ
. 2022 Sep;
378:e071375.
PMID: 36100263
Objective: To determine the efficacy and safety of extended duration perioperative thromboprophylaxis by low molecular weight heparin when assessing disease-free survival in patients undergoing resection for colorectal cancer. Design: Multicentre,...
10.
Goss G, Spaans J, Huntsman D, Asmis T, Andrews Wright N, Duciaume M, et al.
Curr Oncol
. 2022 May;
29(5):3171-3186.
PMID: 35621648
Inuit are the Indigenous Arctic peoples and residents of the Canadian territory of Nunavut who have the highest global rate of lung cancer. Given lung cancer's mortality, histological and genomic...